Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pregabalin controlled release - GL PharmTech

Next Previous
X
Search
Drug Profile

Pregabalin controlled release - GL PharmTech

Alternative Names: GLA5PR; GLA5PR GLARS; GLA5PR GLARS-NF1; GLA5PR GLARS-NF3; Pregabalin GLARS; Pregabalin QD

Latest Information Update: 31 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GL PharmTech
  • Developer Daewon Pharmaceutical
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Gabapentinoids; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Neuropathic pain

Most Recent Events

  • 17 Sep 2019 GL Pharm Tech Corporation initiates a phase I trial for Neuropathic pain (In volunteers) in South Korea (PO) (NCT03963362)
  • 24 May 2019 GL Pharm Tech Corporation plans a phase I trial for Neuropathic pain (In volunteers) in June 2019 (PO) (NCT03963362)
  • 08 Jan 2019 GL PharmTech completes a phase III trial for Neuropathic pain in South Korea (NCT03221907)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top